Cochrane Review Group

Urology

69 systematic reviews in Urology ask 1,000 questions. 19.6% have no studies to answer them, 19.8% rest on very low certainty evidence and 21.9% reach moderate or high certainty.

Reviews

Questions

1,000

current versions

No studies

19.6%

Moderate or high

21.9%

No studies 196 · 19.6%Ungraded 33 · 3.3%Very low 198 · 19.8%Low 354 · 35.4%Moderate 206 · 20.6%High 13 · 1.3%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Search questions in Urology

Thinnest evidence

All no studies and very low questions

Question	Effect	Evidence	Status / GRADE
Topical corticosteroids vs placebo or no treatment Change in retractability score · boys up to 18 years old with phimosis Topical corticosteroids for treating phimosis in boys (2024) · Cochrane	no estimate extracted	2 studies · 177 participants	Very low
Serenoa repens in combination with other phytotherapy vs placebo or no intervention Quality of lifeMeasured by IPSS‐QoL score (range 0 to 6) · lower urinary tract symptoms due to benign prostatic hyperplasia Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement (2023) · Cochrane	no estimate extracted	2 studies · 265 participants	Very low
ESWL vs RIRS Quality of life MCID varies by instrument. · people (>14 years) with kidney stones Extracorporeal shock wave lithotripsy (ESWL) versus percutaneous nephrolithotomy (PCNL) or retrograde… (2023) · Cochrane	no estimate extracted	3 studies · 214 participants	Very low
ESWL vs RIRS Complications MCID: 3% absolute difference · people (>14 years) with kidney stones Extracorporeal shock wave lithotripsy (ESWL) versus percutaneous nephrolithotomy (PCNL) or retrograde… (2023) · Cochrane	RR 0.93 [0.63, 1.36]	13 studies · 1305 participants	Very low
Potassium paraaminobenzoate vs placebo Outcomes ( · men with acute (maximum of 12 months) Peyronie's disease with no prior treatment and no evidence of calcified plaques… Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	NR	No studies
Injectional interferon alpha‐2B vs saline Treatment‐related adverse effects · men with chronic (≥ 12 months) Peyronie's disease (single plaque) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	NR	No studies
Injectional interferon alpha‐2B vs saline Degree of penile curvature · men with chronic (≥ 12 months) Peyronie's disease (single plaque) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	1 study · 103 participants	Very low
Injectional interferon alpha‐2B vs saline Discontinuation from treatment · men with chronic (≥ 12 months) Peyronie's disease (single plaque) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	RR 0.63 [0.22, 1.76]	1 study · 117 participants	Very low
Injectional nicardipine vs saline Outcomes ( · men with chronic Peyronie's disease (plaques without calcification) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	NR	No studies
Injectional nicardipine vs saline Patient‐reported ability to have intercourse · men with chronic Peyronie's disease (plaques without calcification) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	NR	No studies
Injectional nicardipine vs saline Quality of life · men with chronic Peyronie's disease (plaques without calcification) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	NR	No studies
Injectional nicardipine vs saline Treatment‐related adverse effects · men with chronic Peyronie's disease (plaques without calcification) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	RR 2.82 [0.12, 66.62]	1 study · 62 participants	Very low

Reviews 69

Non‐pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome

Franco, JVA, Turk, T, et al. · Cochrane Database of Systematic Reviews · 2018

Urology

Thinnest evidence

Reviews 69

Non‐pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome

Taxane‐based chemohormonal therapy for metastatic hormone‐sensitive prostate cancer

Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum‐containing chemotherapy. A Cochrane Rapid Review

Bisphosphonates for advanced prostate cancer

Laparoscopic and robotic‐assisted versus open radical prostatectomy for the treatment of localised prostate cancer

Medical and dietary interventions for preventing recurrent urinary stones in children

Immunotherapy for metastatic renal cell carcinoma

Intravesical electromotive drug administration for non‐muscle invasive bladder cancer

Partial nephrectomy versus radical nephrectomy for clinical localised renal masses

Desmopressin for treating nocturia in men

Alvimopan for recovery of bowel function after radical cystectomy

Intravesical Bacillus Calmette‐Guérin with interferon‐alpha versus intravesical Bacillus Calmette‐Guérin for treating non‐muscle‐invasive bladder cancer

Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia

Surgery versus non‐surgical management for unilateral ureteric‐pelvic junction obstruction in newborns and infants less than two years of age

Non‐steroidal antiandrogen monotherapy compared with luteinising hormone–releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer

Screening for prostate cancer

Psychosocial interventions for men with prostate cancer

Antimicrobial therapy for chronic bacterial prostatitis

Antibiotic prophylaxis for transrectal prostate biopsy